Quantitative proteomics services that support multiplex biomarker testing across diverse clinical sample types.
Leveraging our expertise in proteomics, biomarker quantification can be performed with ease through immunoassays such as Olink®, MSD®, and Ella™, as well as liquid chromatography-based mass spectrometry (LC-MS) using multiple reaction monitoring (MRM) and parallel reaction monitoring (PRM) assays.
Depending on your study’s specifications, including target matrices and endpoint strategy, our team can assist with platform selection and study setup for optimal downstream results.
Our platform agnostic workflow is designed to your study’s specifications, and our scientists can consult your team on the best platform for bioanalysis, which can include:
Automation is incorporated into our sample processing workflows to ensure rapid turnaround time and reproducibility.
Our experts have vast experience handling a wide range of biological matrices, including:
Letting your study requirements, including sample type, drive platform selection will optimize our analytical approach to support the overall success of your clinical trial.
Using validated off-the-shelf (OTS) panels, we can perform biomarker testing for a variety of sample types, including:
Contact us to learn more about our OTS offerings.
When your study needs more, our team has the expertise to develop custom biomarker quantifications assays that undergo rigorous fit-for-purpose validation.
All protocols used are GCLP-compliant and adhere to CPTAC guidelines, ensuring these panels can be seamlessly integrated into your clinical trial at any stage of development.
Our platform agnostic workflow is designed to your study’s specifications, and our scientists can consult your team on the best platform for bioanalysis, which can include:
Automation is incorporated into our sample processing workflows to ensure rapid turnaround time and reproducibility.
Our experts have vast experience handling a wide range of biological matrices, including:
Letting your study requirements, including sample type, drive platform selection will optimize our analytical approach to support the overall success of your clinical trial.
Using validated off-the-shelf (OTS) panels, we can perform biomarker testing for a variety of sample types, including:
Contact us to learn more about our OTS offerings.
When your study needs more, our team has the expertise to develop custom biomarker quantifications assays that undergo rigorous fit-for-purpose validation.
All protocols used are GCLP-compliant and adhere to CPTAC guidelines, ensuring these panels can be seamlessly integrated into your clinical trial at any stage of development.
We offer a vast range of immuno-MRM assay for MS that enables unambiguous biomarker quantification by coupling immunoaffinity enrichment of peptides to LC-MRM. This approach supports multiplexing, can detect PTMs, and complements assays like IHC and flow cytometry for in-depth biological insights.
CellCarta presents a study on the fit-for-purpose validation of BRD4 quantification in PBMCs using PARK-7 as a normalizing protein. This study highlights the advantages of MS-based normalization as a robust, precise alternative to traditional BCA assays for quantitative biomarker applications.
Our biomarker services are robust, precise, and suited for clinical testing.
Vast Platform Offerings
Adaptable, Automated Workflows
Global Reach
Complex Biomarker Expertise
Close Collaboration
Complement our biomarker testing services with these other proteomics offerings to advance your therapeutic development journey.
Brochure
Posters
Posters
CellCarta supports biomarker quantification through several platforms, selected based on your study's requirements. Key options include LC-MS/MS using MRM or PRM assays, and immunoassays such as Olink®, MSD®, and Ella™. Our scientific team will help identify the most relevant platform for your program.
The platform and analysis workflow for biomarker quantification are tailored to your study’s specifications, taking sample matrix, biology, and endpoint strategy into account. This ensures the right platform is selected for your program, avoiding unnecessary experimentation and keeping your timelines on track.
We offer a range of validated OTS panels, including assays for BCMAs, targeted protein degraders (TPDs), and key proteins associated with several neurological pathologies. These panels are compatible with several biological matrices, including serum, plasma, tissue, and more. Custom assay and panel development is also available for programs with specific biomarker testing requirements.
Immuno-MRM is an immunoaffinity enrichment approach coupled to LC-targeted MRM, enabling sensitive and precise protein quantification. This assay supports multiplexing and can detect post-translational modifications (PTMs), making it suitable for large-scale biomarker testing. CellCarta offers several validated immuno-MRM panels covering DNA damage response, immuno-oncology, Ras-MAPK signaling, and HER2 expression. New panels with up to 50 protein targets can also be developed for client-specific needs.
Yes. All assay development and validation protocols follow GCLP compliance standards, and services are delivered through CAP-accredited and CLIA-certified laboratory sites. Our assays and SOPs also undergo rigorous QA/QC review and align with CPTAC standards, ensuring they are ready for integration into clinical trials and regulatory submissions.
